Clinical Trial Update: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of bb2121 in relapsed/refractory and high-risk multiple myeloma has completed, with reported efficacy and safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• bb2121 (idecabtagene vicleucel) (idecabtagene vicleucel)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED